Neogenomics Inc (NASDAQ: NEO) kicked off on Friday, up 3.44% from the previous trading day, before settling in for the closing price of $7.84. Over the past 52 weeks, NEO has traded in a range of $6.08-$19.11.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 10.13%. While this was happening, its average annual earnings per share was recorded 38.64%. With a float of $127.02 million, this company’s outstanding shares have now reached $128.36 million.
Let’s determine the extent of company efficiency that accounts for 2200 employees. In terms of profitability, gross margin is 43.79%, operating margin of -13.06%, and the pretax margin is -11.58%.
Neogenomics Inc (NEO) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Diagnostics & Research Industry. The insider ownership of Neogenomics Inc is 1.30%, while institutional ownership is 100.00%. The most recent insider transaction that took place on May 12 ’25, was worth 48,895. In this transaction Pres & Chief Operating Officer of this company bought 5,700 shares at a rate of $8.58, taking the stock ownership to the 108,280 shares. Before that another transaction happened on May 09 ’25, when Company’s Director bought 7,000 for $8.14, making the entire transaction worth $56,974. This insider now owns 7,000 shares in total.
Neogenomics Inc (NEO) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 38.64% per share during the next fiscal year.
Neogenomics Inc (NASDAQ: NEO) Trading Performance Indicators
Take a look at Neogenomics Inc’s (NEO) current performance indicators. Last quarter, stock had a quick ratio of 1.94. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.61, a number that is poised to hit 0.03 in the next quarter and is forecasted to reach 0.30 in one year’s time.
Technical Analysis of Neogenomics Inc (NEO)
Looking closely at Neogenomics Inc (NASDAQ: NEO), its last 5-days average volume was 1.69 million, which is a drop from its year-to-date volume of 1.78 million. As of the previous 9 days, the stock’s Stochastic %D was 46.06%. Additionally, its Average True Range was 0.65.
During the past 100 days, Neogenomics Inc’s (NEO) raw stochastic average was set at 15.57%, which indicates a significant decrease from 52.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 189.41% in the past 14 days, which was higher than the 106.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.08, while its 200-day Moving Average is $13.62. However, in the short run, Neogenomics Inc’s stock first resistance to watch stands at $8.26. Second resistance stands at $8.41. The third major resistance level sits at $8.68. If the price goes on to break the first support level at $7.84, it is likely to go to the next support level at $7.58. Should the price break the second support level, the third support level stands at $7.43.
Neogenomics Inc (NASDAQ: NEO) Key Stats
The company with the Market Capitalisation of 1.04 billion has total of 128,695K Shares Outstanding. Its annual sales at the moment are 660,570 K in contrast with the sum of -78,730 K annual income. Company’s last quarter sales were recorded 168,040 K and last quarter income was -25,920 K.
